[Abstact] In order to investigate the therapeutic effect of Runtonglaimi pill on slow transit constipation (STC) mice and its possible therapeutic mechanism. The chemical constituents and target sites of citrus aurantium, atractylodes, and scorpion scorpion were searched by the Chinese Medicine System Pharmacology Analysis Platform (TCMSP). The genes related to STC were searched for by “slow transit constipaton” using the GenCards database. Targets and disease targets intersect genes to construct a compound-target network. 50 mice were divided into blank control group, model control group, positive control group, low-dose group and high-dose group. The STC constipation model was established by oral gavage with loperamide hydrochloride capsule (1.5mg/kg). After successful model, the positive control group was given mosapride citrate tablets (2.5mg/kg) by oral gavage; the low-dose group and high-dose group were given Runtonglaimi pill dilutions 0.05ml/ 10g, 0.1ml/ 10g oral gavage treatment, 2 times per day, a total of 7 days. The propensity of charcoal in the mice, the number of stool cells in the colon, the pathological structure of the colon, and the expression of cox-1 and cox-2 in the colon of the mice were measured. The result show that a total of 35 active compounds were screened by network pharmacology. Twenty-one compounds and 42 targets were involved in network construction. Among them, PTGS1 (cox-1) had the highest degree of connectivity with active compounds. Animal experiments show that Runtonglaimi pill can improve the intestinal propulsion rate of slow transit constipation mice, reduce the number of stool cells in the colon, restore the structure of the colon, and reduce the cox-1 and cox- in the colon of slow transit constipation mice(P<0.01). It is concluded that Runtonglaimi pill can alleviate slow transit constipation, and can relieve slow transit constipation by adjusting cox-1 and cox-2.